ClinicalTrials.Veeva

Menu

Imaging Characteristics of a Follow-up 18F-AV-1451 Scan

A

Avid Pharmaceuticals

Status and phase

Terminated
Phase 2

Conditions

Alzheimer's Disease

Treatments

Drug: Florbetapir F 18
Drug: Flortaucipir F18
Procedure: Brain PET Scan

Study type

Interventional

Funder types

Industry

Identifiers

NCT02051764
18F-AV-1451-A04

Details and patient eligibility

About

This study will evaluate the imaging characteristics of flortaucipir in subjects with a previous flortaucipir scan in order to assess the rate of change of tau deposition over time.

Enrollment

44 patients

Sex

All

Ages

50+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Have a previous 18F-AV-1451 brain scan
  • Can tolerate up to two Positron Emission Tomography (PET) imaging sessions and a Magnetic Resonance Imaging (MRI) scan
  • Ability to provide informed consent

Exclusion criteria

  • Current clinically significant psychiatric disease
  • Are claustrophobic
  • Current clinically significant cardiovascular disease or ECG abnormalities, or additional risk factors for Torsades de Pointes
  • Current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer
  • Females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception
  • Have had a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

44 participants in 1 patient group

Follow-up Flortaucipir PET Scan
Experimental group
Treatment:
Procedure: Brain PET Scan
Drug: Flortaucipir F18
Drug: Florbetapir F 18

Trial contacts and locations

4

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems